These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 11086866)

  • 21. HIV-1 reverse transcriptase inhibitors.
    El Safadi Y; Vivet-Boudou V; Marquet R
    Appl Microbiol Biotechnol; 2007 Jun; 75(4):723-37. PubMed ID: 17370068
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Reliability: nevirapine. Highly effective + favorable influence on lipid profile].
    MMW Fortschr Med; 2005 Apr; 147 Spec No 1():42-3. PubMed ID: 16385872
    [No Abstract]   [Full Text] [Related]  

  • 23. How to start antiretroviral therapy?
    Horster S; Goebel FD
    Infection; 2004 Jun; 32(3):184-5. PubMed ID: 15188082
    [No Abstract]   [Full Text] [Related]  

  • 24. Standard treatments for HIV, Spring 1997.
    Smith D
    AIDS Treat News; 1997 Apr; (No 269):4-5. PubMed ID: 11364255
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Key clinical trials of non-nucleoside reverse transcriptase inhibitors in the treatment of chronic HIV-1 infection in adults.
    Williams I
    J HIV Ther; 2008 Mar; 13(1):19-23. PubMed ID: 18953269
    [No Abstract]   [Full Text] [Related]  

  • 26. AIDS 2000. Clinical treatment: overview.
    Carr A; Yarchoan R
    AIDS; 2000; 14 Suppl 3():S187-8. PubMed ID: 11086861
    [No Abstract]   [Full Text] [Related]  

  • 27. Guidance offered in drug combination choices.
    AIDS Alert; 1997 Dec; 12(12):135-7. PubMed ID: 11364831
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Favorable new data for nevirapine. Antiretroviral effect confirmed--and also lipid profile].
    MMW Fortschr Med; 2004 Apr; 146 Spec No 1():58-60. PubMed ID: 15373051
    [No Abstract]   [Full Text] [Related]  

  • 29. After the drugs: what's next?
    Schouten JT
    Res Initiat Treat Action; 1998 Dec; 4(7):9-10. PubMed ID: 11366085
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical utility of resistance testing.
    Stebbing J; Gazzard BG
    J HIV Ther; 2002 Nov; 7(4):75-9. PubMed ID: 12733604
    [No Abstract]   [Full Text] [Related]  

  • 31. First-line antiretroviral therapy in resource-limited settings: time to reconsider?
    Adlington R; Richens J; Shahmanesh M
    J Infect Dis; 2009 May; 199(9):1407; author reply 1407-8. PubMed ID: 19358673
    [No Abstract]   [Full Text] [Related]  

  • 32. Guidelines for the treatment of HIV.
    Newsline People AIDS Coalit N Y; 1999 Jan; ():31-3. PubMed ID: 11367185
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Nucleoside reverse transcriptase inhibitors. Sex-specific effectiveness and tolerance].
    MMW Fortschr Med; 2000 Mar; 142 Suppl 1():42-3. PubMed ID: 10863310
    [No Abstract]   [Full Text] [Related]  

  • 34. Effectiveness and durability of non-nucleoside reverse transcriptase inhibitor-based therapy in HIV clinical practice.
    Kan VL
    AIDS; 2007 Apr; 21(7):880-2. PubMed ID: 17415048
    [No Abstract]   [Full Text] [Related]  

  • 35. Possible new treatment strategy for HIV/AIDS patients.
    AIDS Read; 2000 Oct; 10(10):578-9. PubMed ID: 11068798
    [No Abstract]   [Full Text] [Related]  

  • 36. HIV-associated lipodystrophy syndrome.
    Mauss S
    AIDS; 2000; 14 Suppl 3():S197-207. PubMed ID: 11086863
    [No Abstract]   [Full Text] [Related]  

  • 37. Antiretroviral drug trials.
    Van Rompay KK; Marthas ML
    Science; 1997 Jun; 276(5318):1482-4. PubMed ID: 9190679
    [No Abstract]   [Full Text] [Related]  

  • 38. A compromise strategy for patients with multiple drug failure.
    Montaner JS; Harris M; Harrigan R; Hogg R; Wood E
    AIDS; 2001 Dec; 15(18):2470. PubMed ID: 11774840
    [No Abstract]   [Full Text] [Related]  

  • 39. Antiretroviral drug trials.
    Breckenridge A; Kitchen V; Darbyshire JH
    Science; 1997 Jun; 276(5318):1481-2; author reply 1443-4. PubMed ID: 9190678
    [No Abstract]   [Full Text] [Related]  

  • 40. Access and activism: the ethics of providing antiretroviral therapy in developing countries.
    von Schoen Angerer T; Wilson D; Ford N; Kasper T
    AIDS; 2001; 15 Suppl 5():S81-90. PubMed ID: 11816178
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.